Source-grounded facts extracted from ENDRA Life Sciences Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ENDRA Life Sciences Inc. issued up to an aggregate of 100,000 shares of Common Stock of warrant to the Placement Agent.
“the Company will issue to the Placement Agent prefunded warrants (the “Placement Agent Prefunded Warrants”) to purchase up to an aggregate of 100,000 shares of Common Stock as compensation.”
ENDRA Life Sciences Inc. issued up to 1,156,774 shares of Common Stock of warrant to an accredited investor for per share exercise price of $6.57.
“warrants (the “Common Warrants”) to purchase an aggregate of up to 1,156,774 shares of Common Stock at a per share exercise price of $6.57. Each share of Common Stock (or Pre-Funded Warrant in lieu thereof) and accompanying Common Warrants were sold at a combined purchase price of $6.57.”
ENDRA Life Sciences Inc. issued 578,387 shares of common stock to an accredited investor for combined purchase price of $6.57.
“aggregate of 578,387 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (the “Prefunded Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,156,774 shares of Common Stock at a per share exercise price of $6.57. Each share of Common Stock (or Pre-Funded Warrant in lieu thereof) and accompanying Common Warrants were sold at a combined purchase price of $6.57.”
ENDRA Life Sciences Inc. entered into Side Letter Agreement with the Purchaser (effective 2026-05-27).
“Concurrently with the entry into the Securities Purchase Agreement, the Company and the Purchaser entered into a side letter agreement (the “Side Letter Agreement”).”
ENDRA Life Sciences Inc. entered into Securities Purchase Agreement with an accredited investor valued at approximately $3.8 million (effective 2026-05-27).
“On May 27, 2026, ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with an accredited investor (the “Purchaser”) pursuant to which the Company agreed to sell and issue to the Purchaser in a private placement offering (the “Offering”) an aggregate of 578,387 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (the “Prefunded Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,156,774 shares of Common Stock at a per share exercise price of $6.57.”
ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“April 20, 2026, the Staff issued a letter to the Company indicating that, because the Company’s stockholders’ equity as reported in its Annual Report on Form 10-K for the year ended December 31, 2025 was $2,260,120, the Company is no longer in compliance with Minimum Stockholders’ Equity Requirement. The Staff’s letter indicated that the Company’s non-compliance would result in the delisting of the Company’s securities from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company intends to timely request a hearing before the Panel, which”
ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2025 results: net income net loss of $3.2 million.
“in the fourth quarter of 2025 decreased to $1.6 million, compared with $4.3 million in the same period last year. As a result, the net loss in the fourth quarter of 2025 was $3.2 million, compared with a net loss of $4.2 million in the fourth quarter of 2024. 2025 Financial Results During 2025 the Company benefitted from actions taken throughout 2024 to”
ENDRA Life Sciences Inc. announced a restructuring with charges of approximately $51,000.
“on March 19, 2026, the Company reduced the number of its employees in order to reduce cash expenditures and extend its operational runway. As a result, the Company expects to incur pre-tax cash charges of approximately $51,000 associated with severance payments to former employees.”
ENDRA Life Sciences Inc.: Increased authorized common stock from 20,000,000 shares to 1,000,000,000 shares via Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation (effective 2025-12-10).
“At the Annual Meeting, the Company’s stockholders approved and adopted a Certificate of Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of Company’s common stock, par value $0.0001 (the “Common Stock”), from 20,000,000 shares to 1,000,000,000 shares (the “Share Increase Amendment”). The Share Increase Amendment was filed with the Secretary of State of the State of Delaware on December 10, 2025 and was effective upon filing.”
ENDRA Life Sciences Inc. issued 44,660 shares of Common Stock of warrant to Placement Agent for exercise price of $9.47 per share.
“on the Closing Date, the Company issued to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 44,660 shares of Common Stock at an exercise price of $9.47 per share.”
ENDRA Life Sciences Inc. issued 400,000 shares of Common Stock of warrant to Arca Investment Management, LLC.
“the Company issued to Arca warrants to purchase an aggregate of 400,000 shares of Common Stock (the “Advisory Warrants”)”
ENDRA Life Sciences Inc. issued Prefunded Warrants of warrant to certain accredited investors for exercise price of $0.0001 per share.
“Each of the Prefunded Warrants is exercisable for one share of Common Stock at the exercise price of $0.0001 per share of Common Stock underlying the Prefunded Warrant”
ENDRA Life Sciences Inc. issued up to 1,488,680 shares of Common Stock of warrant to certain accredited investors for per share exercise price of $6.32.
“Each of the Common Warrants is exercisable for one share of Common Stock at the exercise price of $6.32 per share of Common Stock”
ENDRA Life Sciences Inc. issued 744,340 shares of common stock to certain accredited investors for combined purchase price of $6.57.
“at a per share exercise price of $6.32. Each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants were sold at a combined purchase price of $6.57. In accordance with the rules of the Nasdaq Stock Market, a member of the Company’s board of directors who participated in the Offering (the “Director Participant”) purchased”
ENDRA Life Sciences Inc. issued 44,660 shares of warrant to Lucid Capital Markets, LLC for exercise price of $9.47 per share.
“In connection with the Offering, in addition to customary placement fees and reimbursement of certain expenses of the Placement Agent, on the Closing Date, the Company issued to the Placement Agent warrants (the “Placement Agent Warrants”) to purchase up to an aggregate of 44,660 shares of Common Stock at an exercise price of $9.47 per share.”
ENDRA Life Sciences Inc. issued 400,000 shares of warrant to Arca Investment Management, LLC for exercise prices ranging from $6.95 to $7.50.
“aggregate of 400,000 shares of Common Stock (the “Advisory Warrants”). Advisory Warrants in respect of 100,000 shares are exercisable immediately for an exercise price equal to $6.95, or 110% of the exercise price of the Common Warrants. Advisory Warrants in respect of 300,000 shares become exercisable in the event that AUM exceeds certain thresholds within”
ENDRA Life Sciences Inc. issued 1,488,680 shares of warrant to accredited investors for exercise price $6.32 per share.
“On October 10, 2025, ENDRA Life Sciences Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain accredited investors (the “Purchasers”) pursuant to which the Company agreed to sell and issue to the Purchasers in a private placement offering (the “Offering”) an aggregate of 744,340 shares (the “Shares”) of common stock of the Company, par value $0.0001 per share (the “Common Stock”), and/or prefunded warrants in lieu thereof (the “Prefunded Warrants”), and warrants (the “Common Warrants”) to purchase an aggregate of up to 1,488,680 shares of Common Stock at a per share exercise price of $6.32.”
ENDRA Life Sciences Inc. issued 744,340 shares of common stock to accredited investors for $6.57 per share.
“at a per share exercise price of $6.32. Each share of common stock (or pre-funded warrant in lieu thereof) and accompanying warrants were sold at a combined purchase price of $6.57. In accordance with the rules of the Nasdaq Stock Market, a member of the Company’s board of directors who participated in the Offering (the “Director Participant”) purchased”
ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“May 27, 2025, ENDRA Life Sciences Inc. (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, because the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 was $1,752,885, the Company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires companies listed on The Nasdaq Capital Market to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing. Nasdaq’s letter has no immediate impact on the listing of the Company’s common stock, which will cont”
ENDRA Life Sciences Inc.: Amendment to Certificate of Incorporation to effect a 1-for-35 reverse stock split (effective 2024-11-07).
“On November 4, 2024, Company filed with the Secretary of State of the State of Delaware an amendment to the Certificate of Incorporation to effect the Reverse Stock Split (the “Amendment”) at 12:01 a.m. Eastern Time on November 7, 2024.”
Alexander Tokman was appointed as Acting Chief Executive Officer and Chairman at ENDRA Life Sciences Inc..
“Appointment of Alexander Tokman as Acting Chief Executive Officer Effective August 13, 2024, the Board appointed Alexander Tokman as the Company’s acting Chief Executive Officer and Chairman.”
Francois Michelon resigned as Chief Executive Officer and Director at ENDRA Life Sciences Inc..
“Francois Michelon Resignation On August 12, 2024, ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) and Francois Michelon mutually agreed on Mr. Michelon’s resignation as the Company’s Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”), effective August 12, 2024.”
Richard Jacroux was appointed as Head of Finance at ENDRA Life Sciences Inc..
“On August 8, 2024, the Company’s Board of Directors (the “Board of Directors”) appointed Richard Jacroux as Head of Finance.”
Irina Pestrikova resigned as Senior Director, Finance at ENDRA Life Sciences Inc..
“On August 5, 2024, Irina Pestrikova notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of her resignation as the Company’s Senior Director, Finance, effective August 7, 2024.”
ENDRA Life Sciences Inc. reported the three months ended March 31, 2024 results: net income $2.8 million, or $0.26 per share, EPS $0.26 per share.
“Net loss in the first quarter of 2024 was $2.8 million, or $0.26 per share, compared with a net loss of $2.9 million, or $0.93 per share, in the first quarter of 2023.”
ENDRA Life Sciences Inc. reported the fiscal quarter ended March 31, 2024 results: net income We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2024.
“On May 10, 2024, ENDRA Life Sciences Inc. (the “Company”) filed a Registration Statement (the “Prospectus”) on Form S-1/A (No. 333-278842) pursuant to the Securities Act of 1933, as amended (the “Securities Act”), relating to a public offering (the “Offering”) of shares of the Company’s common stock and warrants to purchase shares of the Company’s common stock. The Prospectus contains select preliminary unaudited estimated financial results for the fiscal quarter ended March 31, 2024.”
ENDRA Life Sciences Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 3, 2024, ENDRA Life Sciences Inc. (the “Company”) received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, because the closing bid price for the Company’s common stock listed on Nasdaq was below $1.00 for 30 consecutive trading days, the Company no longer meets the minimum bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Marketplace Rule 5550(a)(2), requiring a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The notification has no immediat”
ENDRA Life Sciences Inc. reported the year ended December 31, 2023 results: net income Net loss in 2023 was $10.1 million, or $1.58 per share, EPS $1.58 per share.
“Net loss in 2023 was $10.1 million, or $1.58 per share, compared with a net loss of $13.2 million, or $4.56 per share, in 2022.”
ENDRA Life Sciences Inc. reported the quarter and year ended December 31, 2023 results: net income Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, EPS $0.17 per share.
“Net loss in the fourth quarter of 2023 was $1.5 million, or $0.17 per share, compared with a net loss of $3.3 million, or $1.04 per share, in the fourth quarter of 2022.”
ENDRA Life Sciences Inc. reported the quarter ended September 30, 2023 results: net income Net loss in the third quarter of 2023 was $3.1 million, or $0.40 per share, EPS $0.40 per share.
“ENDRA Life Sciences Inc . (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS ® ), today reports financial results for the three and nine months ended September 30, 2023 and provides a business update.”
ENDRA Life Sciences Inc. reported the quarter ended June 30, 2023 results: net income Net loss in the second quarter of 2023 was $2.6 million, or $0.43 per share, EPS $0.43 per share.
“On August 14, 2023, ENDRA Life Sciences Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2023.”
ENDRA Life Sciences Inc. shareholders approved Ratification of RBSM LLP as independent registered public accounting firm at the 2023-08-09 meeting.
“Proposal 4 – The Company’s stockholders ratified the appointment of RBSM LLP by the Audit Committee of the Board of Directors as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023: For Against Abstain 2,794,638 126,032 63,296”
ENDRA Life Sciences Inc. shareholders approved Advisory vote on frequency of future say-on-pay votes at the 2023-08-09 meeting.
“Proposal 3 – The Company’s stockholders recommended, on an advisory basis, holding advisory votes on the compensation paid to the Company’s named executive officers every year: One Year Two Years Three Years Abstain Broker Non-Votes 1,743,563 111,671 241,373 48,983 838,376”
ENDRA Life Sciences Inc. shareholders approved Advisory vote on compensation of named executive officers at the 2023-08-09 meeting.
“Proposal 2 – The Company’s stockholders approved, on an advisory basis, the compensation paid to the Company’s named executive officers: For Against Abstain Broker Non-Votes 1,733,406 340,392 71,792 838,376”
ENDRA Life Sciences Inc. shareholders approved Election of five directors to serve until the next annual meeting at the 2023-08-09 meeting.
“The certified results of the matters voted upon at the meeting, which are more fully described in the Proxy Statement for the Annual Meeting as filed with the Securities and Exchange Commission on May 24, 2023 (the “Proxy Statement”), are as follows: Proposal 1 – The Company’s stockholders elected the five directors nominated by the Company’s Board of Directors to serve until the next annual meeting of stockholders and the election of their successors: For Withheld Broker Non-Votes Francois Michelon 2,024,988 120,602 838,376 Louis J. Basenese 1,628,081 517,509 838,376 Anthony DiGiandomenico 1,976,138 169,452 838,376 Michael Harsh 1,958,901 186,689 838,376 Alexander Tokman 2,054,532 91,058 838,376”
ENDRA Life Sciences Inc. reported the three months ended March 31, 2023 results: net income $2.9 million, EPS $0.93 per share.
“First Quarter 2023 Financial Results In the first quarter of 2023, our operating expenses were $2.9 million, unchanged from the first quarter in 2022. Increases in research and development and general and administrative expenses were offset by decreases in sales and marketing expenses. Net loss in the first quarter of 2023 was $2.9 million, or $0.93 per share, compared with a net loss of $2.9 million, or $1.33 per share, in the first quarter of 2022.”
ENDRA Life Sciences Inc. entered into Warrant Agreement with VStock Transfer, LLC (effective 2023-05-02).
“On May 2, 2023, the Company entered into a Warrant Agent Agreement setting forth the terms and conditions of the warrants (the “Warrant Agreement”) with its transfer agent, VStock Transfer, LLC, which will act as warrant agent for the warrants.”
ENDRA Life Sciences Inc. entered into Underwriting Agreement with Newbridge Securities Corporation valued at approximately $4.5 million (effective 2023-04-27).
“On April 27, 2023, ENDRA Life Sciences Inc. (the “Company,” “we,” “us” and “our”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Newbridge Securities Corporation (the “Underwriter”), relating to the issuance and sale (the “Offering”) of 3,750,000 shares of our common stock and warrants to purchase up to 1,875,000 shares of our common stock.”
ENDRA Life Sciences Inc. reported the quarter ended March 31, 2023 results: revenue no revenue, net income net loss of approximately $2.8 million.
“We expect no revenue for the quarter ended March 31, 2023 and did not have revenue for the quarter ended March 31, 2022. We expect to record a net loss of approximately $2.8 million for the quarter ended March 31, 2023, compared to a net loss of approximately $2.9 million for the quarter ended March 31, 2022.”
ENDRA Life Sciences Inc. reported the year ended December 31, 2022 results: net income Net loss in 2022 was $13.2 million, or $4.56 per share, EPS $4.56 per share.
“Net loss in 2022 was $13.2 million, or $4.56 per share, compared with a net loss of $11.2 million, or $5.55 per share, in 2021.”
ENDRA Life Sciences Inc. reported the fourth quarter of 2022 results: net income Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, EPS $1.04 per share.
“Net loss in the fourth quarter of 2022 was $3.3 million, or $1.04 per share, compared with a net loss of $3.1 million, or $1.48 per share, in the fourth quarter of 2021.”
Renaud Maloberti resigned as Chief Commercial Officer at ENDRA Life Sciences Inc..
“On December 21, 2022, Renaud Maloberti notified ENDRA Life Sciences Inc. (“ENDRA” or the “Company”) of his resignation as the Company’s Chief Commercial Officer, effective January 13, 2023.”
ENDRA Life Sciences Inc. amended Collaborative Research Agreement with General Electric Company valued at Extended term to December 16, 2024 (effective 2022-12-16).
“On December 16, 2022, ENDRA Life Sciences Inc. (the “Company”) entered into Amendment 5 (the “Amendment”) to that certain Collaborative Research Agreement between the Company and General Electric Company (“GE”), dated as of April 22, 2016, as amended (the “Agreement”). The Amendment extends the term of the Agreement to December 16, 2024.”
ENDRA Life Sciences Inc.: Effected a 1-for-20 reverse stock split of common stock through a Certificate of Amendment to the Fourth Amended and Restated Certificate of Incorporation (effective 2022-12-09).
“On December 8, 2022, ENDRA Life Sciences Inc. (the “Company”) filed a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation (the “Certificate of Incorporation”) with the Secretary of State of Delaware to effect a 1-for-20 reverse stock split of the shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (Eastern time) on December 9, 2022 (the “Reverse Stock Split”).”
ENDRA Life Sciences Inc. shareholders approved Amendment to Amended and Restated Certificate of Incorporation to effect a reverse stock split of common stock at a ratio between 1-for-2 and 1-for-30 at the 2022-11-29 meeting.
“The certified results of the matter voted upon at the meeting, which is more fully described in the definitive proxy statement filed with the Securities and Exchange Commission on October 17, 2022, are as follows: Proposal 1 – The stockholders of the Company approved an amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) to effect, at the discretion of the Company’s Board of Directors (the “Board”) on or prior to the one-year anniversary of the date of the Special Meeting, a reverse stock split of the Company’s common stock at a stock split ratio between 1-for-2 and 1-for-30, with the ultimate ratio to be determined by the Board in its sole discretion, the implementation and timing of which shall be subject to the discretion of the Board, with votes cast as follows: For Against Abstain 21,057,265,393 7,433,237,535 5,832,047,971”
ENDRA Life Sciences Inc. reported third quarter of 2022 results: net income $3.4 million, EPS $0.05 per share.
“Net loss in the third quarter of 2022 was $3.4 million, or $0.05 per share”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.